As per the 2023 United States National Survey on Drug Use and Health (NSDUH), 48.5 million Americans (aged 12 and above) were affected by substance use disorder in the past year, accounting for 16.7% of the population. Genetics, including the influence of environmental factors on gene expression, contribute to around 40%-60% of an individual’s risk of drug addiction. With a substantial proportion of the population impacted by substance use disorders, the demand for effective medications for combating addiction is increasing.
Report Coverage
The Substance (Drug) Abuse Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into substance (drug) abuse drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for substance (drug) abuse. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The substance (drug) abuse pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from substance (drug) abuse.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to substance (drug) abuse.
Substance (Drug) Abuse Drug Pipeline Outlook
Substance (drug) abuse includes a pattern of excessive use of psychoactive drugs that can lead to physical, emotional, or social harm. Drug abuse involves both psychological and physical dependence on drugs such as pain medications or alcohol. Genetic predisposition and environmental factors can increase a person’s risk of addiction. Additionally, people with mental health disorders and teenagers are more prone to drug use and addiction compared to other populations.
Medication along with some type of behavioral therapy or counseling is considered the first line of treatment for people suffering from opioid addiction. Common medications include methadone, buprenorphine, extended-release naltrexone, and lofexidine which help in treating opioid drug addiction and withdrawal. With increasing funding and support for addiction research and treatment programs from governmental and non-governmental organizations, the substance (drug) abuse pipeline is anticipated to witness a steady expansion in the coming years.
Substance (Drug) Abuse – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of substance (drug) abuse drugs based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecule
- Biologics
- Peptide
- Monoclonal Antibody
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase I and II cover a major share of the total clinical trials for substance (drug) abuse.
Substance (Drug) Abuse – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the substance (drug) abuse pipeline analysis include small molecule, biologics, peptide, monoclonal antibody, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for substance (drug) abuse.
Substance (Drug) Abuse Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the substance (drug) abuse drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in substance (drug) abuse clinical trials:
- Tonix Pharmaceuticals, Inc.
- Tempero Bio, Inc.
- Power Life Sciences Inc.
- Tris Pharma, Inc.
- Aelis Farma
- Wecare Probiotics Co., Ltd.
- Theranova, L.L.C.
- Inventage Lab., Inc.
Major drugs currently in the drug pipeline are as follows:
Drug: TMP-301
Sponsored by Tempero Bio, Inc., the objective of this participant-blinded, placebo-controlled Phase II study is to assess the preliminary efficacy, tolerability, and safety of TMP-301 in around 100 adult patients with alcohol use disorder (AUD).
Drug: Probenecid
This Phase II clinical trial is aimed at investigating the use of the drug probenecid in alleviating the symptoms of opioid withdrawal in people affected by dependence on opioid medications. The interventional study has enrolled an estimated 40 subjects and is expected to be completed by December 2025.
Reasons To Buy This Report
The Substance (Drug) Abuse Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for substance (drug) abuse. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within substance (drug) abuse pipeline insights.
Key Questions Answered in the Substance (Drug) Abuse – Pipeline Insight Report
- What is the current landscape of substance (drug) abuse pipeline drugs?
- How many companies are developing Substance (Drug) Abuse drugs?
- How many phase III and phase IV drugs are currently present in substance (drug) abuse pipeline drugs?
- Which companies/institutions are leading the substance (drug) abuse drug development?
- What is the efficacy and safety profile of substance (drug) abuse pipeline drugs?
- What are the opportunities and challenges present in the substance (drug) abuse drug pipeline landscape?
- Which company is conducting major trials for substance (drug) abuse drugs?
- What geographies are covered for substance (drug) abuse clinical trials?
- What are emerging trends in substance (drug) abuse clinical trials?
Substance Drug Abuse Market Report
Global Clinical Trials Market
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Substance (Drug) Abuse
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Substance (Drug) Abuse
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Substance (Drug) Abuse
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Substance (Drug) Abuse: Epidemiology Snapshot
- 5.1 Substance (Drug) Abuse Incidence by Key Markets
- 5.2 Substance (Drug) Abuse – Patients Seeking Treatment in Key Markets
- 6 Substance (Drug) Abuse: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Substance (Drug) Abuse: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Substance (Drug) Abuse, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Substance (Drug) Abuse Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Substance (Drug) Abuse Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Buprenorphine Injection, Drug: Buprenorphine Sublingual Product
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Substance (Drug) Abuse Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: TNX-1300 (Injection)
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Probenecid
- 11.2.3 Drug: TMP-301
- 11.2.4 Drug: Cannabidiol (CBD)
- 11.2.5 Other Drugs
- 12 Substance (Drug) Abuse Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: Vivitrol Injectable Product, Drug: IVL3004, Drug: IVL4002
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Substance (Drug) Abuse Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Substance (Drug) Abuse, Key Drug Pipeline Companies
- 14.1 Tonix Pharmaceuticals, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Tempero Bio, Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Power Life Sciences Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Tris Pharma, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Aelis Farma
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Wecare Probiotics Co., Ltd.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Theranova, L.L.C.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Inventage Lab., Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook